EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Hansa Biopharma AB (0RC7) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Hansa Biopharma AB SEK 8.62, price SEK 33.47, upside -74.3%, quality 42 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · GB · ISIN SE0002148817

HB Thin data Aug 13, 2026

Hansa Biopharma AB

0RC7 · LSE

Weakest SetupStrongly overvalued and low quality.

!Fair value kr 8.62 · Strongly overvalued (−74.3%)
!Quality 42/100
!Mixed Growth (revenue 5y +105.3 %/yr)
!Negative equity (buybacks among others) · negative free cash flow
!Narrow moat 30/100
!Evidence only low, so the estimate is less certain

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 158.97 kr 21.31 Fair Value kr 8.62 Jun 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range kr 21.31 – kr 158.97 · fair‑value band kr 5.69 – kr 10.77 · the kr 33.47 price screens above the kr 8.62 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe.

Show more

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It also develops HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD) and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was formerly known as Hansa Medical AB (publ) and changed its name to Hansa Biopharma AB (publ) in December 2018. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Stock analysis

Hansa Biopharma AB (0RC7) currently trades at kr 33.47, while our model-based Fair Value estimate is kr 8.62, 74.3% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the evidence level at low.

Scenario range: kr 5.69 (bear) to kr 10.77 (bull), the price of kr 33.47 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Hansa Biopharma AB reported revenue of 222M SEK in FY2025 versus 33.9M SEK in FY2021, a compound +60.0%/yr. Reported net income was −529M SEK in FY2025.

Key figures

Market cap 2.9B SEK (≈ $293M) · P/S ratio 15.5 · Return on equity −4,177% · Return on assets (EBIT) −57.8% · Operating margin −335% · Revenue (TTM) 189M SEK · Revenue growth (YoY) −2.1% · Free cash flow −549M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 28% below its 52-week high and 41% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −74%, 0RC7 screens richer than that median.

Notify me when 0RC7 reaches fair value

Put 0RC7 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 42/100

Of which business quality 42 · Market factors (momentum, volatility) 30

Profitability 6
Margins and returns on capital today
Quality Growth 88
Are margins and returns improving?
Cashflow 34
Earnings quality: real cash, not paper profit
Fin. Strength 50
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 9
Calm price path (market factor)
Momentum 44
Price trend over the last 3–12 months (market factor)
52W Momentum 30
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+29.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+105.3%
Start year 2020 (pandemic). Over 10 years: +42.0% a year
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+57.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−6,970.8% (2020) → −234.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

0RC7 screens overvalued: fair value 74% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Hansa Biopharma AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Hansa Biopharma AB · Fair Value
kr 8.62 −74%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Hansa Biopharma AB Fair Value". https://www.fairvalue-calculator.com/stock/0RC7

Frequently asked questions

Is Hansa Biopharma AB (0RC7) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of kr 8.62 versus a price of kr 33.47, about −74% upside (overvalued).
What is the fair value of 0RC7?
Our model-based fair value for Hansa Biopharma AB is kr 8.62 (as of Aug 13, 2026), built from audited fundamentals. The current price: kr 33.47.
What is the quality score of 0RC7?
Hansa Biopharma AB has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hansa Biopharma AB (0RC7)?
Our model-based price target is the fair value of kr 8.62 (as of Aug 13, 2026) from 1 valuation models. Cautious scenario kr 5.69, optimistic scenario kr 10.77. It is a calculation from audited fundamentals, not an analyst target.
What is the Hansa Biopharma AB stock forecast for 2026?
Our models put fair value at kr 8.62, about −74% upside versus a price of kr 33.47 (overvalued). Cautious scenario kr 5.69, optimistic scenario kr 10.77. The calculation is refreshed regularly with new filings.
What is the revenue of Hansa Biopharma AB (0RC7)?
Hansa Biopharma AB reported trailing-twelve-month revenue of about 189M SEK (latest available figure, as of Aug 13, 2026).
What is the intrinsic value of Hansa Biopharma AB (0RC7)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hansa Biopharma AB it is kr 8.62 per share (as of Aug 13, 2026), against a price of kr 33.47. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Hansa Biopharma AB stock overvalued or undervalued in 2026?
As of Aug 13, 2026, 0RC7 trades above its calculated fair value: price kr 33.47, fair value kr 8.62, a gap of about −74% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0RC7?
No. The price is what the market pays today (kr 33.47); the fair value is what the company's own numbers justify (kr 8.62). For Hansa Biopharma AB the two are kr 24.85 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hansa Biopharma AB worth?
The market values Hansa Biopharma AB at about 2.9B SEK (market capitalisation, as of Aug 13, 2026). Per share that is kr 33.47; our models calculate a fair value of kr 8.62 per share.
What do the bullish and bearish scenarios say about 0RC7?
Our models span a range for Hansa Biopharma AB: cautious scenario kr 5.69, base kr 8.62, optimistic kr 10.77 per share (as of Aug 13, 2026, price kr 33.47). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0RC7 from its 52-week high?
Hansa Biopharma AB trades at kr 33.47, about 28% below its 52-week high of kr 46.40 and 41% above the low of kr 23.75 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of kr 8.62 is for.
Which stocks are comparable to Hansa Biopharma AB?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hansa Biopharma AB stock attractive at the current price?
The data as of Aug 13, 2026: price kr 33.47, calculated fair value kr 8.62 (−74%), Quality Score 42/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0RC7 calculated?
We run Hansa Biopharma AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 8.62, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Hansa Biopharma AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hansa Biopharma AB (0RC7)?
The closing price on Oct 2, 2026 was kr 33.47. Our model-based fair value is kr 8.62, about −74% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hansa Biopharma AB right now?
The price sits above even our optimistic bull case (kr 10.77). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 5.69 to kr 10.77) leaves room in how you read the outcome.

Key figures of Hansa Biopharma AB

How large is the market capitalisation of Hansa Biopharma AB (0RC7)?
The market capitalisation of Hansa Biopharma AB is 2.9B SEK (≈ $293M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hansa Biopharma AB (0RC7)?
The price-to-sales ratio of Hansa Biopharma AB is 15.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of Hansa Biopharma AB (0RC7)?
The return on equity (ROE) of Hansa Biopharma AB is −4,177% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hansa Biopharma AB (0RC7)?
On an EBIT basis the return on assets of Hansa Biopharma AB is −57.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hansa Biopharma AB (0RC7)?
The operating margin of Hansa Biopharma AB is −335% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hansa Biopharma AB (0RC7)?
Revenue at Hansa Biopharma AB is growing −2.1% versus a year earlier (3y avg +12.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Hansa Biopharma AB (0RC7) generate?
The free cash flow of Hansa Biopharma AB is −549M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Hansa Biopharma AB (0RC7) carry?
The net debt of Hansa Biopharma AB is 233M SEK (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Continue in the live analysis

Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.